Curcumin composition for osteoarthritis and joint health

A stable curcumin formulation with curcuminoids in polymorphic forms and excipients addresses bioavailability issues, effectively treating osteoarthritis by improving joint health and muscle recovery.

KR103046309B1Active Publication Date: 2026-11-10OMNIACTIVE HEALTH TECH LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020227018949
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-03
Filing Date
2020-12-02
Publication Date
2026-11-10
Estimated Expiration
2040-12-02

AI Technical Summary

Technical Problem

Curcumin's low bioavailability, low water solubility, instability at neutral and basic pH, low absorption, rapid metabolism, and short half-life limit its therapeutic use, particularly for oral delivery systems.

Method used

A stable curcumin formulation comprising curcuminoids in various polymorphic forms, such as amorphous and crystalline, with optional proportions, and at least one pharmaceutically acceptable excipient, including hydrophilic carriers, antioxidants, stabilizers, and pH adjusters, to enhance absorption and bioavailability.

Benefits of technology

The formulation improves curcumin's stability and bioavailability, providing effective prevention, improvement, and maintenance of arthritis, specifically osteoarthritis, by enhancing joint mobility, flexibility, reducing inflammation, and promoting muscle recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022058609747-PCT00010_ABST
    Figure 112022058609747-PCT00010_ABST
Patent Text Reader

Abstract

The present invention relates to a stable curcumin composition for the prevention, improvement, and maintenance of arthritis, more specifically, osteoarthritis. The stable curcumin composition is composed of curcuminoids alone or together with at least one pharmaceutically and / or functionally acceptable excipient to form a stable curcumin composition with improved absorption and bioavailability. The composition comprises an optional percentage of curcumin in amorphous and crystalline polymorphic forms together with optional excipients, such as pH regulators and / or stabilizers, and optionally hydrophilic carriers, antioxidants, diluents, anti-caking agents, emulsifiers, lipids, and surfactants, and is safe for consumption and possesses improved stability and bioavailability, and improves the symptoms of arthritis and related pathological conditions when administered to subjects who require it.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a stable curcumin composition for the prevention, improvement, and maintenance of arthritis, more specifically, osteoarthritis. More specifically, the stable curcumin composition comprises curcuminoids in various polymorphic forms, such as amorphous and crystalline, and / or in optional proportions, thereby improving the stability of curcumin in an alkaline pH environment of the intestine to enhance bioavailability. Background Technology

[0002] Arthritis is a more specific term referring to damage or inflammation of one or more joints. This condition often manifests as pain, swelling, fever, redness, and limited movement. Knee osteoarthritis is a type of disease caused by the degeneration of articular cartilage between the bones. As a result of this cartilage reduction, increased friction occurs between the bones, leading to the development of painful bone spurs.

[0003] Curcumin is derived from the rhizomes of *Curcuma longa* and has traditionally been used to treat inflammation, skin wounds, and tumors. Overall, while curcumin is associated with various health issues, its therapeutic use is limited due to low bioavailability, low water solubility, instability at neutral and basic pH, low absorption, rapid metabolism, and a short half-life. Curcumin is a Class IV drug (low solubility and low permeability) based on the Biopharmaceutical Classification System (BCS). Many strategies have been developed to overcome these limitations, particularly for oral delivery systems.

[0004] US2016089343A1 is a formulation for the topical delivery of a therapeutically effective amount of curcumin that provides serum levels of curcumin sufficient to treat diseases such as head and neck disorders and upper respiratory and digestive disorders.

[0005] EP3275430A1 relates to an aqueous solution for intravenous infusion containing curcumin and / or one or more curcumin derivatives, dimethyl sulfoxide, one or more solubilizing agents, sodium selenite, and a buffer in an aqueous infusion medium, as well as a concentrate containing curcumin and / or one or more curcumin, dimethyl sulfoxide, one or more solubilizing agents, and sodium selenite for the preparation thereof.

[0006] KN Pushpakumari International Journal of Pharmaceutical Sciences and Research an Impact factor (2019): 1.230 cite score (2017): 0.27 presents comparative bioavailability data of two turmeric formulations containing curcuminoids with various compositions compared to a standard turmeric extract. This literature is completely silent on the effects of curcumin on osteoarthritis.

[0007] To find a satisfactory solution to persistent problems, there is a strong need to develop stable curcumin formulations for the treatment, prevention, and maintenance of arthritis, more specifically osteoarthritis. Stable curcumin compositions contain curcuminoids in various polymorphic forms, such as amorphous and crystalline, and / or in optional proportions to improve bioavailability. Stable curcumin compositions are composed of curcuminoids alone or together with at least one pharmaceutically and / or functionally acceptable excipient to form stable curcumin compositions with enhanced absorption and bioavailability.

[0008] Object of the present invention

[0009] The main objective of the present invention is to develop a stable curcumin formulation for the prevention, improvement, and maintenance of arthritis.

[0010] Another objective of the present invention is to provide a stable curcumin formulation available in an oral administration form and having improved bioavailability.

[0011] Another objective of the present invention is to develop a stable curcumin formulation containing curcuminoids in various polymorphic forms, such as amorphous and crystalline forms, and / or in selective proportions to improve absorption and bioavailability.

[0012] Another objective of the present invention is to develop a stable curcumin formulation that includes a curcuminoid alone and / or together with at least one pharmaceutically and / or functional food-acceptable excipient to form a stable curcumin composition with improved absorption and bioavailability.

[0013] Another objective of the present invention is to develop a stable curcumin formulation that forms a stable curcumin composition with improved absorption and bioavailability, composed of curcuminoid alone and / or at least one pH adjuster and stabilizer, optionally with a hydrophilic carrier, antioxidant, diluent, anti-caking agent, emulsifier, lipid, and surfactant.

[0014] A further aspect of the present invention is to provide a method for preparing a stable curcumin composition suitable for formulation into tablets, capsules, mixed powders, licaps, ointments, pastes, lotions, liniment preparations, mouthwashes, gargles, consumable dry syrups, liquid syrups, health drinks, diet drinks, fruit juices, soft drinks, etc.

[0015] Another objective of the present invention is to provide a stable curcumin composition for the prevention, improvement, and maintenance of arthritis, more specifically osteoarthritis and related conditions, such as reduction in articular cartilage, joint mobility, joint flexibility, and inflammation.

[0016] A further objective of the present invention is to provide a stable curcumin composition for use in improving muscle strength and muscle performance, reducing muscle pain and damage, and promoting faster muscle recovery.

[0017] Summary of the present invention

[0018] According to one aspect of the present invention, a stable curcumin composition with improved bioavailability is provided, comprising the following:

[0019] i) Curcumin containing 0 to 15% of crystalline polymorphic curcuminoids and 85 to 100% of amorphous polymorphic curcuminoids, and

[0020] ii) At least one pharmaceutically or functionally acceptable ingredient selected from hydrophilic carriers, antioxidants, stabilizers, pH adjusters, solubilizers, fats, and anti-caking agents. Brief explanation of the drawing

[0021] Brief description of the attached drawings Fig. 1 : X-ray diffraction (XRD) graph of the composition prepared according to Example 1 Fig. 2 : X-ray diffraction (XRD) graph of the composition prepared according to Example 2 Fig. 3 : X-ray diffraction (XRD) graph of the composition prepared according to Example 3 Fig. 4 : X-ray diffraction (XRD) graph of the composition prepared according to Example 4 Fig. 5 . Effect of curcumin (Cur) on knee joint protein expression at IL-β (A), IL-6 (B), TNF-α (C), and NF-κβ (D) levels in monosodium uroacetate (MIA)-induced osteoarthritis (OA) rats. Bars represent standard deviations. Blots were repeated at least three times (n = 3), and representative blots are shown. Asterisks above the line indicate statistical differences between groups (ANOVA and post-hoc tests of turkey, ** P<0.01; *** P<0.001; **** P <O.OOO1). OA, 골관절염; Cur, 커큐민; MIA, 모노소듐 요도아세테이트; IL-1β, 인터루킨-1β; IL-6, 인터루킨-6; TNF-α, 종양 괴사 인자 α; NF-κβ, 핵인자 카파 β. Fig. 6. Effect of curcumin (Cur) on knee joint protein expression at the levels of collagen type 2 (A), MMP-3 (B), COX-2 (C), and LOX-5 (D) in monosodium urethral acetate (MIA)-induced osteoarthritis (OA) rats. Bars represent standard deviations. Blots were repeated at least three times (n = 3), and representative blots are shown. Asterisks above the line indicate statistical differences between groups (ANOVA and post-hoc tests of Türkiye, ** P<0.01; *** P<0.001; **** P <O.OOO1). OA, 골관절염; Cur, 커큐민; MIA, 모노소듐 요도아세테이트; MMP-3, 매트릭스 메탈로프로테이나제-3; CCOX-2, 사이클로옥시게나제-2; LOX-5, 5-리폭시게나제 Fig. 7 . Effects of curcumin (Cur) on the knee joint in rats with monosodium urethral acetate (MIA)-induced osteoarthritis (OA). Representative radiographs (A) obtained at the end of the experiment are shown. Mean Kellgren-Lawrence scores are expressed as ± standard deviation (B). Asterisks indicate statistical differences in Kellgren-Lawrence scores between groups indicated by bars (Mann-Whitney U after Kruskal-Wallis; * P<0.05 ** P<0.01; compared to the OA group). Fig. 8 Effect of curcumin (Cur) on knee joint histopathology in monosodium urethral acetate (MIA)-induced osteoarthritis (OA) rats. Representative histopathological images of hematoxylin-eosin (A) and toluidine blue (B) staining obtained at the end of the experiment are shown. Mean values ​​of Mankin scores are presented as ± standard deviation. Stars above the line indicate statistical differences in Mankin scores between groups (C) indicated by bars (Mann-Whitney U after Kruskal-Wallis; * P<0.05, compared to the OA group). Fig. 9. Effects of curcumin (Cur) on knee swelling (A), left knee joint diameter (B), right knee joint diameter (C), and the ratio of right diameter to left diameter (D) in rats with monosodium uroacetate (MIA)-induced osteoarthritis (OA). Asterisks above the line indicate statistical differences between groups (ANOVA and post-hoc tests of turkey, ** P<0.01; *** P<0.001; **** P <O.OOO1). Fig. 10 . Effects of curcumin (Cur) on foot area (B) and stride length (D) in rats with monosodium uroacetate (MIA)-induced osteoarthritis (OA). Representative measurements of foot area (A) and stride length (C) are shown. Asterisks above the line indicate statistical differences between groups (ANOVA and post-hoc tests of turkey, * P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001). Fig. 11 : Total plasma curcuminoid concentration of curcumin composition versus reference. Specific details for implementing the invention

[0022] According to an embodiment of the present invention, a stable curcumin formulation comprises curcuminoids in various polymorphic forms, such as amorphous and crystalline, in selective proportions to improve bioavailability. According to a further embodiment of the present invention, a stable curcumin formulation comprises curcuminoids alone and / or together with at least one excipient to prevent, improve, and maintain arthritis, more specifically osteoarthritis, thereby forming a stable curcumin composition with improved absorption and bioavailability.

[0023] In the present invention, the term “curcumin composition” is generally used in this specification to refer to a composition that comprises various polymorphic forms of curcuminoids, such as amorphous and crystalline, in selective proportions, alone and / or together with at least one excipient, to form a stable curcumin composition with increased absorption and bioavailability.

[0024] Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is the major curcuminoid of *Curcuma longa*, a medicinal Indian spice commonly known as turmeric, a perennial herb of the *Zingiberaceae* (ginger) family. The term "curcumin" can be interpreted as falling within the scope of the term curcuminoids and may generally include curcumin components such as curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Commercial products referred to as "curcumin" may contain these components, and there may be other components belonging to the curcuminoid class. Curcumin extracts contain total curcuminoids in the range of 40–99%.

[0025] According to a further embodiment of the present invention, a curcumin composition comprising a curcuminoid present in a range of 10-90% w / w of the composition.

[0026] According to a further embodiment of the present invention, a stable curcumin formulation is formed by including a curcuminoid alone and / or together with at least one excipient to form a stable curcumin composition with increased absorption and bioavailability. More preferably, the stable curcumin composition is formulated using an excipient selected from the group consisting of (but not limited to) a hydrophilic carrier, an antioxidant, a solvent, an emulsifier, a surfactant, a solubilizer, a stabilizer, a pH adjuster, a binder, an anti-caking agent, a fat, and / or a combination thereof.

[0027] In another embodiment, the solid hydrophilic carrier used in the preparation of the curcumin composition is selected from the group such as (but not limited to) cellulose derivatives, polyacrylates, polyethylene glycol, povidone, starch and starch derivatives, gums, sugars, pectin, plant polysaccharides, proteins, such as casein, whey protein, soy protein, pea protein, sugar alcohols, glucose, polyvinylpyrrolidone, etc.

[0028] According to a preferred embodiment, the hydrophilic carrier is hydroxypropyl methylcellulose.

[0029] According to an additional embodiment, the hydrophilic carrier is present in the range of 1-90% w / w of the composition.

[0030] In another embodiment, in the preparation of the curcumin composition, the antioxidant is selected from the group such as (but not limited to) natural tocopherol, mixed tocopherol, ascorbyl palmitate, rosemary extract, epigallocatechin gallate, catechin, and ascorbic acid.

[0031] According to an additional embodiment, the antioxidant is present in the range of 0.1-10% w / w of the composition.

[0032] In another embodiment, in the preparation of a stable curcumin composition, the solvent is selected from the group such as (but not limited to) isopropyl alcohol, acetone, methanol, alcohol, ethyl acetate, ethanol, methylene dichloride, water, and mixtures thereof. The temperature maintained to obtain a homogeneous mass may be ambient temperature to 80°C; preferably, in the range of 25°C to 60°C.

[0033] According to an additional embodiment, the solvent is present in the range of 40-98% w / w of the composition.

[0034] In another embodiment, in the preparation of a stable curcumin composition, the emulsifier is selected from the group such as (but not limited to) polysorbates, sugar alcohols, glycerol and derivatives thereof.

[0035] According to an additional embodiment, the emulsifier is present in the range of 0.1-10% w / w of the composition.

[0036] In another embodiment, in the preparation of a stable curcumin composition, the surfactant is selected from the group such as (but not limited to) sugar alcohols, sugar esters (e.g., sucrose stearate and others), and esters of sugar alcohols (e.g., sorbitan and others). According to a further embodiment, the surfactant is present in the range of 0.1-10% w / w of the composition.

[0037] In another embodiment, in the preparation of the curcumin composition, the solubilizing agent is selected from the group such as (but not limited to) propylene glycol alginate, sugar alcohol, sugar ester, phospholipid, lecithin, d-limonene, vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate), sodium lauryl sulfate, and beta-cyclodextrin.

[0038] According to an additional embodiment, the solubilizing agent is present in the range of 0.1-40% w / w of the composition.

[0039] In another embodiment, in the preparation of the curcumin composition, the stabilizer is selected from the group such as (but not limited to) glyceryl monostearate, sugar alcohols, triglycerides, antioxidants, monoglycerides, and phospholipids.

[0040] According to an additional embodiment, the stabilizer is present in the range of 0.1 to 10% w / w of the composition.

[0041] In another embodiment, in the preparation of the curcumin composition, the pH adjuster is selected from the group such as (but not limited to) citric acid, trisodium citrate, lactic acid, L-arginine, calcium carbonate, and magnesium carbonate.

[0042] According to an additional embodiment, the pH adjuster is present in the range of 0.1-10% w / w of the composition.

[0043] In another embodiment, in the preparation of the curcumin composition, the binder is selected from the group such as (but not limited to) hydroxypropyl cellulose, gelatinized and starch.

[0044] According to an additional embodiment, the binder is present in the range of 0.1-10% w / w of the composition.

[0045] In another embodiment, in the preparation of the curcumin composition, the anti-caking agent is selected from the group such as (but not limited to) colloidal silicon dioxide, magnesium stearate, stearic acid, and mannitol.

[0046] According to an additional embodiment, the anti-caking agent is present in the range of 0.1-10% w / w of the composition.

[0047] In another embodiment, the fat used in the preparation of the curcumin composition is selected from the group such as medium-chain triglycerides, long-chain triglycerides, vegetable oils, esters of fatty acids, hydrocarbons such as terpenes, and monoglycerides (but not limited thereto).

[0048] According to an additional embodiment, fat is present in the range of 0.1 to 40% w / w of the composition.

[0049] According to a further embodiment of the present invention, the stable curcumin composition described herein exhibits increased bioavailability and is available in an orally administered solid, semi-solid, or liquid form selected from volumes such as powders, granules, pellets, beads, caplets, tablets, capsules, soft gel capsules, solutions, emulsions, suspensions, dispersions, etc. (but is not limited thereto).

[0050] According to another embodiment of the present invention, the curcumin composition is in the form of granules.

[0051] According to another embodiment of the present invention, the curcumin composition is in the form of a powder.

[0052] In some embodiments, a method for preparing a stable curcumin composition with improved stability and bioavailability for osteoarthritis comprises the following:

[0053] (i) a step of dissolving one or more excipients in a solvent or a mixture thereof while continuously stirring at 50-80℃ for 10-15 minutes;

[0054] (ii) a step of dissolving curcumin in a solvent or a mixture thereof while stirring continuously for 5-10 minutes at 50-80℃, and then cooling the temperature to 30-40℃; and

[0055] (iii) a step of forming a homogeneous mass by adding other excipients, such as a hydrophilic carrier, antioxidant, diluent, stabilizer, pH adjuster, anti-caking agent, fat, emulsifier, and surfactant, to a solvent; (iv) a step of forming a dry mass by removing the solvent by evaporation; and

[0056] (v) A step of grinding the dry lump to form fine powder.

[0057] In step (ii), the removal of the solvent can be performed by vacuum distillation or evaporation techniques, or by spray drying techniques. The resulting dry mass is ground using, for example, a mortar and pestle, a mixer-grinder, a multi-mill, a ball mill, a jet mill, etc.

[0058] According to a further embodiment of the present invention, a stable curcumin composition is used for the prevention, improvement, and maintenance of arthritis, more specifically osteoarthritis.

[0059] According to a further embodiment of the present invention, a stable curcumin composition is used for the prevention, improvement, and maintenance of osteoarthritis.

[0060] According to a further embodiment of the present invention, a stable curcumin composition is used for maintaining joint health.

[0061] According to a further embodiment of the present invention, stable curcumin is provided, exhibiting increased joint mobility, comfortable movement for ease of daily activities, improved walking performance, increased joint flexibility, reduced joint stiffness, reduced joint discomfort / pain, reduced inflammation, and reduced cartilage degeneration.

[0062] According to a further embodiment of the present invention, a stable curcumin composition is used to improve muscle strength and muscle performance, reduce muscle pain and muscle damage, and promote faster muscle recovery.

[0063] Example 1:

[0064]

[0065] (Total Curcuminoids. %) = Amount of Extract (%) * Extract Concentration (% Curcuminoids) / 100 = 24 * 95 / 100 = 22.8%

[0066] The method for preparing the composition is defined in the following stepwise manner:

[0067] i) Citric anhydride, glyceryl monostearate, and lecithin are dissolved in a mixture of isopropyl alcohol and methylene dichloride while heating at 55-60°C. A curcumin extract containing curcumin, demethoxy curcumin, and bisdemethoxy curcumin is added while heating at 55-60°C and stirred for 25-40 minutes until completely dissolved. The solution is cooled to 30-40°C.

[0068] ii) Hydroxypropyl methylcellulose and sodium lauryl sulfate are further added while stirring.

[0069] iii) Medium-chain triglyceride oil, d-limonene, and tocopherol were added to the solution from step (ii) under stirring. The solution was stirred for 35-45 minutes to obtain a homogeneous solution.

[0070] iv) A homogeneous solution was used as the feed liquid for a spray dryer. The powder obtained from the spray dryer was further dried in a vacuum dryer at a temperature of 50-90°C, then colloidal silicon dioxide was added, followed by sieving and blending. The resulting product was a yellowish-orange, free-flowing, homogeneous powder.

[0071] v) Figure 1 shows the X-ray powder diffraction (XRD) of a curcumin composition having 1.2% crystalline polymorphs and 98.8% amorphous polymorphs of curcuminoids.

[0072] Example 2 :

[0073]

[0074] (Total Curcuminoids. %) = Amount of Extract (%) * Extract Concentration (% Curcuminoids) / 100 = 24 * 95 / 100 = 22.8%

[0075] The method for preparing the composition is defined in the following stepwise manner:

[0076] i) Citric anhydride, glyceryl monostearate, and lecithin are dissolved in a mixture of isopropyl alcohol and methylene dichloride while heating at 55-60°C. A curcumin extract containing curcumin, demethoxycurcumin, and bisdemethoxycurcumin is added while heating at 55-60°C and stirred for 25-40 minutes until completely dissolved. The solution is cooled to 30-40°C.

[0077] ii) Hydroxypropyl methylcellulose is additionally added while stirring.

[0078] iii) Medium-chain triglyceride oil and tocopherol were added to the solution from step (ii) under stirring. The solution was stirred for 35-45 minutes to obtain a homogeneous solution.

[0079] iv) A homogeneous solution was used as the feed liquid for a spray dryer. The powder obtained from the spray dryer was further dried in a vacuum dryer at a temperature of 50-90°C, then colloidal silicon dioxide was added, followed by sieving and blending. The resulting product was a yellowish-orange, free-flowing, homogeneous powder.

[0080] v) Figure 2 shows the X-ray powder diffraction (XRD) of a curcumin composition having 1.2% crystalline polymorphs and 98.8% amorphous polymorphs of curcuminoids.

[0081] Example 3:

[0082]

[0083] (Total Curcuminoids. %) = Amount of Extract (%) * Extract Concentration (% Curcuminoids) / 100 = 24 * 95 / 100 = 22.8%

[0084] i) Citric anhydride, glyceryl monostearate, and lecithin are dissolved in a mixture of ethanol and ethyl acetate while heating at 55-60°C. Curcumin extract is added while heating at 55-60°C and stirred for 25-40 minutes until completely dissolved. The solution is cooled to 30-40°C.

[0085] ii) Hydroxypropyl methylcellulose is additionally added while stirring.

[0086] iii) Medium-chain triglyceride oil, d-limonene, and tocopherol were added to the solution from step (ii) under stirring. The solution was stirred for 35-45 minutes to obtain a homogeneous solution.

[0087] iv) A homogeneous solution was used as the feed liquid for a spray dryer. The powder obtained from the spray dryer was further dried in a vacuum dryer at a temperature of 50-90°C, then colloidal silicon dioxide was added, followed by sieving and blending. The resulting product was a yellowish-orange, free-flowing, homogeneous powder.

[0088] v) Figure 3 shows the X-ray powder diffraction (XRD) of a curcumin composition having 2% crystalline polymorphs and 98% amorphous polymorphs of curcuminoids.

[0089] Example 4:

[0090]

[0091] (Total Curcuminoids. %) = Amount of Extract (%) * Extract Concentration (% Curcuminoids) / 100 = 71.15 * 90 / 100 = 64.04%

[0092] i) Citric anhydride, glyceryl monostearate, and lecithin are dissolved in a mixture of ethanol and ethyl acetate while heating at 55-60°C. Curcumin extract is added while heating at 55-60°C and stirred for 25-40 minutes until completely dissolved. The solution is cooled to 30-40°C.

[0093] ii) Hydroxypropyl methylcellulose is additionally added while stirring.

[0094] iii) Medium-chain triglyceride oil and tocopherol were added to the solution from step (ii) under stirring. The solution was stirred for 35-45 minutes to obtain a homogeneous solution.

[0095] iv) A homogeneous solution was used as the feed liquid for a spray dryer. The powder obtained from the spray dryer was further dried in a vacuum dryer at a temperature of 50-90°C, then colloidal silicon dioxide was added, followed by sieving and blending. The resulting product was a yellowish-orange, free-flowing, homogeneous powder.

[0096] v) Figure 4 shows the X-ray powder diffraction (XRD) of a curcumin composition having 4% crystalline polymorphs and 96% amorphous polymorphs of curcuminoids.

[0097] Example 5

[0098]

[0099] (Total Curcuminoids. %) = Amount of Extract (%) * Extract Intensity (% Curcuminoids) / 100 = 86.5 * 95 / 100 = 82.18%

[0100] i) Citric anhydride, glyceryl monostearate, and lecithin are dissolved in a mixture of ethanol and ethyl acetate while heating at 55-60°C. Curcumin extract is added while heating at 55-60°C and stirred for 25-40 minutes until completely dissolved. The solution is cooled to 30-40°C.

[0101] ii) Hydroxypropyl methylcellulose is additionally added while stirring.

[0102] iii) Medium-chain triglyceride oil, d-limonene, and tocopherol were added to the solution from step (ii) under stirring. The solution was stirred for 35-45 minutes to obtain a homogeneous solution.

[0103] iv) A homogeneous solution was used as the feed liquid for a spray dryer. The powder obtained from the spray dryer was further dried in a vacuum dryer at a temperature of 50-90°C, then colloidal silicon dioxide was added, followed by sieving and blending. The resulting product was a yellowish-orange, free-flowing, homogeneous powder.

[0104] At the beginning of the following description, it should be understood that the description is intended to illustrate only specific forms of the invention. However, such specific forms are merely exemplary embodiments and should not be construed restrictively as implying a limitation on the scope of the invention.

[0105] Clinical Trial Study 1:

[0106] Objective: The current study evaluated the efficacy of a curcumin composition (test product) in monosodium uroacetate (MIA)-induced osteoarthritis.

[0107] Test product: Curcumin composition consisting of curcuminoids manufactured by OmniActive Health Technologies Limited, India.

[0108] Dosage 1: Formulation 100 mg / kg (Total curcuminoids 20 mg / kg) (Example 1: 1.2% crystalline polymorphs and 98.8% amorphous polymorphs of curcuminoids)

[0109] Dosage 2: Formulation 200 mg / kg (Total curcuminoids 40 mg / kg) (Example 1: 1.2% crystalline polymorphs and 98.8% amorphous polymorphs of curcuminoids)

[0110] Experimental design: Female Wistar rats (8 weeks old) were randomly assigned to the groups defined below (n=7 each):

[0111] I. Normal Control Group

[0112] II. Osteoarthritis Group

[0113] III. Osteoarthritis, Curcumin composition dose 1 (100 mg / kg formulation) group and

[0114] IV. Osteoarthritis, curcumin composition dose 2 (200 mg / kg formulation) group.

[0115] To induce osteoarthritis in the rat model, the right knee of the rats was shaved, locally anesthetized with xylazine (10 mg / kg) and ketamine hydrochloride (50 mg / kg), and then disinfected with 70% alcohol. 3 mg of MIA was dissolved in 50 μL of saline and injected into the right knee joint via the subpatellar ligament using a 0.3 ml insulin syringe equipped with a 29-G needle. The control group received an injection of 50 μL of saline. Two weeks after the MIA injection, Formulation 1 and Formulation 2 were dissolved in 1 mL of saline and administered orally for four weeks. All rats were observed every other day to assess knee joint swelling.

[0116] Four weeks after the rats were sacrificed, blood and knee joint samples were collected for follow-up experiments. Blood samples were centrifuged at 3,000 rpm for 10 minutes, and the collected serum was stored at -20 ℃ until the day of analysis.

[0117] Sample preparation:

[0118] The curcumin composition according to the present invention is as follows:

[0119] Test samples for 100 mg / kg and 200 mg / kg were prepared according to Example 1 with the provided process parameters.

[0120] Biochemical analysis

[0121] Serum for MDA (malondialdehyde) was analyzed by HPLC. Antioxidant enzymes (SOD, CAT, GSHPx), IL-1β, IL-6, IL-10, and TNF-α were measured using relevant commercial kits according to the enzyme-linked immunosorbent assay (ELISA) method.

[0122] Western blot analysis

[0123] Articular cartilage samples were analyzed for the expression of TNF-α, IL-6, IL-1β, nuclear factor kappa B, cyclooxygenase-2 (COX-2), collagen type 2, CRP, 5-LOX, MMP3, and cartilage oligomer matrix protein (COMP) using the Western blot technique.

[0124] Histological analysis

[0125] Histological changes were evaluated to confirm the product's effect on cartilage degeneration in the knee joints of MIA-induced osteoarthritis rats. After rat sacrifice, each knee joint was fixed in 10% formalin at 4°C for 24 hours and decalcified with 5% hydrochloric acid at 4°C for 4 days. After decalcification, specimens were dehydrated in graded acetone and embedded in paraffin. Sections (thickness, 2–3 µm) were stained with 0.2% hematoxylin and 1% eosin for 5 and 3 minutes, respectively. Histological preparations were analyzed, and photographs were taken under a microscope using a digital image capture camera.

[0126] Example 1

[0127] The purpose of the study was to demonstrate the effect of the curcumin composition according to the present invention on serum inflammation markers.

[0128] Methods: Animals were sacrificed, and serum samples were collected and evaluated for serum biomarkers measured using a relevant commercial kit according to the enzyme-linked immunosorbent assay (ELISA) method as shown in Table 1 and exemplarily provided in Figure 5.

[0129] Table 1:

[0130]

[0131] abbreviation:

[0132] OA: Osteoarthritis group

[0133] Cur1: Curcumin composition dose 1 (100 mg / kg formulation)

[0134] Cur2: Curcumin composition dose 2 (200 mg / kg formulation)

[0135] TNF-α: Tumor necrosis factor α; IL-1β: Interleukin-1β; IL-6: Interleukin-6; IL-10: Interleukin-10; COMP: Cartilage oligometric matrix protein; CRP: c-reactive protein.

[0136] Statistical comparisons are indicated by different superscripts (ad) in the same row (P < 0.05, *post-hoc test for ANOVA and Turkey). The mean values ​​of the items are expressed as ± standard deviation.

[0137] conclusion:

[0138] In Table 1 and Figure 5, serum inflammatory markers such as TNFα, IL1β, IL-6, COMP, and CRP, which are responsible for the induction of inflammation and related pathology, were increased during OA, and treatment with curcumin composition 1 and curcumin composition 2 reduced these levels in a statistically significant manner. The levels of the cytokine IL-10, which were reduced during OA, were restored by treatment.

[0139] Example 2

[0140] The purpose of the study was to demonstrate the effect of the curcumin composition on serum antioxidant markers.

[0141] method Animals were sacrificed, serum samples were collected, and serum antioxidant markers were evaluated. MDA serum was analyzed by HPLC. Antioxidant enzymes (SOD, CAT, GSHPx) were measured using relevant commercial kits according to the enzyme-linked immunosorbent assay (ELISA) method, and the data are shown in the table below.

[0142] Table 2:

[0143]

[0144] MDA: Malondialdehyde; SOD: Superoxide dismutase; GSH-Px: Glutathione peroxidase; CAT: Catalase. Statistical comparisons are indicated by different superscripts (ad) in the same row (P < 0.05, * (ANOVA and post-hoc test of Türkiye). The mean values ​​of the markers are verified as ± standard deviation.

[0145] conclusion:

[0146] MDA, a marker of oxidative stress that plays a key role in the pathogenesis of OA, significantly increased during OA and significantly decreased during treatment. Similarly, treatment significantly improved the levels of antioxidant enzymes, SOD, CAT, and GSH-Px, as shown in Table 2.

[0147] Example 3

[0148] The purpose of this study was to demonstrate the effect of curcumin compositions on inflammatory markers in synovial joint tissue.

[0149] method: Animals were sacrificed, synovial tissue samples were collected, and evaluated for inflammation markers by Western blot as shown in Figure 5.

[0150] conclusion:

[0151] Protein levels of inflammatory markers were observed as follows: IL-β (A), IL-6 (B), TNF-α (C), and NF-κβ (D) were increased in OA rats as measured by densitometric analysis of relative intensity relative to the control group after β-actin normalization to ensure the same protein loading, after being measured by Western blot. The blots were repeated at least three times (n = 3), and a representative blot (E) is shown.

[0152] Treatment with two doses (100 & 200 mg / kg) of curcumin compositions was observed to reduce the levels of inflammatory markers in joint tissues in a statistically significant manner.

[0153] Example 4

[0154] The purpose of the study was to demonstrate the effects of curcumin compositions on cartilage degeneration and inflammation markers in synovial joint tissues.

[0155] method: Animals were sacrificed and synovial tissue samples were collected and evaluated for markers of cartilage degeneration and inflammation by Western blot as shown in Figure 6.

[0156] conclusion:

[0157] Protein levels of collagen degradation markers such as collagen type 2 (A), MMP-3 (B), and inflammatory markers COX-2 (C) and LOX-5 (D), as described below, were increased in OA rats as measured by densiometric analysis of relative intensity relative to a control after β-actin normalization to ensure the same protein loading, after being measured by Western blot. The blots were repeated at least three times (n = 3), and a representative blot (E) is shown.

[0158] It was observed that the levels of markers of cartilage degeneration and inflammation in joint tissues were reduced in a statistically significant manner by treating with two doses of curcumin composition.

[0159] Example 5

[0160] The purpose of the study was to demonstrate the effect of curcumin compositions on the joint structure of synovial joints as evaluated by X-ray image analysis.

[0161] method: The animals were evaluated for the structural integrity of the synovial joints by radiographic analysis as shown in Figure 7 and Table 4.

[0162] Table 4 . Kellgren-Lawrence scoring system (Kellgren and Lawrence, 1957).

[0163]

[0164] conclusion :

[0165] The induction of OA was observed to be associated with a loss of joint structural integrity, as observed in the radiograph (A) obtained at the end of the experiment. Significant improvement in joint structure was observed after treatment with curcumin composition 1 and curcumin composition 2. The above results were further verified by measuring the mean value of the Kellgren-Lawrence score (B) with ± standard deviation.

[0166] Example 6

[0167] The purpose of the study was to demonstrate the effect of curcumin composition on the morphological analysis of synovial joint tissue.

[0168] Methods: Animals were sacrificed, synovial tissue samples were collected, fixed in 10% formalin at 4°C for 24 hours, decalcified with 5% hydrochloric acid at 4°C for 4 days, dehydrated in graded acetone, and embedded in paraffin. Sections 2-3 µm thick were stained with 0.2% hematoxylin and 1% eosin for 5 minutes and 3 minutes, respectively, histological preparations were analyzed, and photographs were taken with a microscope using a digital image capture camera as shown in Fig. 8.

[0169] conclusion:

[0170] As observed after histopathological images of hematoxylin-eosin (A) and toluidine blue (B) staining obtained at the end of the experiment, significant loss of joint structure and inflammatory infiltration of the joint were observed in the OA condition. This was further verified by the mean value of the Mankin score (C).

[0171] Example 7

[0172] The purpose of the study was to demonstrate the effect of curcumin composition on the morphological analysis of synovial joint tissue.

[0173] Method: As shown in Fig. 9, the knee was visually evaluated for morphological changes in joint pathology, such as knee swelling, knee joint diameter, and the ratio of the right diameter value to the left diameter value.

[0174] conclusion:

[0175] When OA was induced in rats, swelling of the right and left knee joints was observed, which was significantly reduced by treatment with curcumin composition 1 and curcumin composition 2 (A). This was further verified by measuring the left knee joint diameter (B), the right knee joint diameter (C), and the ratio of the right diameter value to the left diameter value, and significant therapeutic effects were observed with curcumin composition 1 and curcumin composition 2.

[0176] Example 8

[0177] The purpose of the study was to demonstrate the effect of curcumin composition on foot area and stride length.

[0178] Methods: Ink was applied to the hind feet of rats using a brush, and the animals were made to run on a track 60 cm long and 7 cm wide covered with white paper. A darkroom chamber was placed at the end of the track to entice the rats. Once the test was complete, the paper was scanned at 300 dpi. Measurements around the foot were defined as foot area (cm²), the distance between the first and fifth toes (cm) as foot width, the same hind foot distance between two steps as stride (cm), the horizontal distance between the left and right feet as base (cm), the distance between the third toe and the heel as foot length (cm), and the foot angle as the angle passing through the hind leg (°). Footprint measurements were quantified using ImageJ software as shown in Fig. 10.

[0179] conclusion :

[0180] Foot area and stride length were significantly reduced due to osteoarthritis. Both foot area and stride length were significantly improved in curcumin composition 1 and curcumin composition 2.

[0181] Clinical Trial Study 2 :

[0182] Objective: The objective of this study was to evaluate the plasma pharmacokinetic profile of curcumin compositions in adult male Sprague Dawleys.

[0183] Select capacity

[0184] A dose of 1000 mg / kg body weight (total curcuminoids 200 mg / kg) was selected for the oral administration route.

[0185] Test product: Curcumin composition according to Example 1

[0186] Reference: Curcumin extract (curcumin extract without arbitrary formulations and polymorphic forms)

[0187] Curcumin extract (conventional curcumin) and any formulations without polymorphisms were generally prepared by extracting the rhizome of turmeric with a solvent and evaporating it to form turmeric oleoresin, and then further crystallizing the turmeric using a suitable solvent. The obtained crystals were dried and obtained as a powder containing 95% curcuminoids.

[0188] Time points (hr): 0.00, 0.25, 0.50, 1.00, 2.00, 3.00, 4.00, 6.00, 8.00 and 24.00

[0189] Table 5:

[0190]

[0191] C max : Peak plasma concentration

[0192] T max : Time to reach peak plasma concentration

[0193] AUC 0-last: Area under the concentration-time curve from time 0 to the last quantifiable concentration

[0194] t 1 / 2 Half-life

[0195] conclusion :

[0196] The curcumin composition showed an AUC 64.71 times higher than the reference curcumin extract.

[0197] Based on the results and conclusions provided for the osteoarthritis model, it was concluded that the same curcumin composition would also have a beneficial effect on muscle health. A cell line study model further verified by the research protocol to investigate the efficacy on muscle health is described below.

[0198] Further studies to demonstrate the effects of curcumin compositions on muscle health are as follows.

[0199] In vitro study:

[0200] Objective: To demonstrate a potential ergogenic curcumin composition (test product) for improving physiological or metabolic responses that may aid in muscle development (preventing muscle protein loss such as in age-related sarcopenia), enhance exercise performance, and alleviate muscle damage and muscle inflammation (DOMS).

[0201] Cell model: C2C12 murine myoblasts

[0202] Experimental approach: Basic analysis was performed according to the study, the selected component to be developed was identified, C2C12 myoblasts were cultured at 37°C in humidified 5% CO2, plated in 24-well plates, and treated after incubation for 24 hours to generate additional information.

[0203] 1. Cytotoxicity Analysis

[0204] 2. Mitochondrial density analysis: The effect of components on mitochondrial biosynthesis is analyzed by measuring and calculating cellular respiration accompanied by an increase in mitochondrial mass.

[0205] 3. Antioxidant capacity: After 24 hours of treatment, the total antioxidant capacity of the C2C12 homogenate was measured.

[0206] 4. Lactate dehydrogenase and creatine kinase activity: LDH and CK activity are used as indicators of muscle cell damage and are evaluated by determining the release of cytoplasmic enzymes lactate dehydrogenase (LDH) and creatine kinase (CK) activity.

[0207] 5. IGF-1 ELISA Analysis: IGF-I exerts acute anabolic effects on protein and carbohydrate metabolism by increasing the cellular uptake of amino acids, and plays an important role in the regulation of skeletal muscle growth.

[0208] In vivo research:

[0209] Objective: To evaluate the effects of a curcumin composition (test product) formulation on the endurance, grip strength, and muscle metabolism of rats.

[0210] Animal and Experimental Design:

[0211] Twenty-one Wistar Albino or Sprag Dooly male rats (20% additional animals), age: 8 weeks, weight: 180 ± 20 g, were housed in an environment controlled by a 12:12 light-dark cycle at 22°C, provided with rat food, and allowed to drink water at will.

[0212] Rats were randomly divided into 3 treatment groups, each containing 7 animals.

[0213] 1. Control group (normal and exercising)

[0214] 2. Curcumin Composition 1 (100 mg / kg formulation)

[0215] 3. Curcumin Composition 2 (200 mg / kg formulation)

[0216] During the screening period, grip strength was measured on the 3rd day. On the 2nd day, a treadmill test was performed.

[0217] Grip strength test:

[0218] The grip strength of rats was evaluated using a force measurement system. The combined grip strength of the forelimbs and hindlimbs, as well as the grip strength of the forelimbs alone, were measured at the end of the oral administration period. This system includes an electronic digital force gauge for determining maximum force. Each rat had its tail held until the pull bar was released. Five consecutive tests were performed for each rat to obtain peak values.

[0219] Treadmill test:

[0220] Running endurance of rats was measured using an animal treadmill. Rats were fasted overnight, sacrificed by cervical dislocation, and blood and gastrocnemius muscle samples were collected. Serum samples were obtained by transferring blood samples into gel biochemistry tubes after centrifugation (5000 rpm for 10 minutes at 4°C). Samples from the liver and gastrocnemius muscle (collected from nearly the same location each time) were rapidly removed, placed on ice, and stored at -80°C until analysis. For biochemical analysis, tissue samples were homogenized within 10 minutes in 10 volumes of cold Tris 10 mM (pH 7.4). The muscle homogenates were centrifuged at 4000 xg for 10 minutes at 4°C to generate a low-velocity supernatant fraction, which was used for lipid peroxide analysis.

[0221] Biochemical analysis:

[0222] Serum glucose, lipid profiles, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, and creatinine levels were analyzed using a portable automated chemical analyzer (Samsung LABGEO PT10V, Samsung Electronics Co., Suwon, Korea). Serum lactate concentrations were measured via enzyme-linked immunosorbent assay (ELISA, Elx-800, Bio-Tek Instruments Inc, Vermont, USA) using a rat lactate assay kit (Cayman Chemical Co., Ann Arbor, Michigan, USA). ELISA (MyBioSource, San Diego, California, USA) is also used to measure serum myoglobin concentrations.

[0223] Malondialdehyde (MDA) levels in muscle tissue were measured by high-performance liquid chromatography (Shimadzu, Tokyo, Japan) using a Shimadzu UV-vis SPD-10 AVP detector and a C18 ODS-3, 5 µm, 4.6 mm x 250 mm column. The activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) were determined using a commercially available kit (Cayman Chemical, Ann Arbor, Michigan, USA) according to the manufacturer's procedure.

[0224] It should be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments and may be embodied in other specific forms without departing from the essential spirit of the invention. Accordingly, the embodiments and examples described herein are to be regarded as exemplary in all respects without limitation, with reference to the appended claims rather than the foregoing description, and it is desirable that all modifications within the equivalent meaning and scope of the invention be included herein.

Claims

Claim 1 A stable curcuminoid composition for the prevention, improvement, and maintenance of osteoarthritis with improved bioavailability, comprising: i) a curcuminoid in a crystalline polymorphic form in the range of 0 to 15% w / w relative to total curcuminoids and a curcuminoid in an amorphous polymorphic form in the range of 85 to 100% w / w relative to total curcuminoids; and ii) at least one pharmaceutically or functionally acceptable ingredient selected from a hydrophilic carrier, an antioxidant, a stabilizer, a pH adjuster, a solubilizer, a fat, and an anticaking agent, wherein the hydrophilic carrier is selected from hydroxypropyl methylcellulose, cellulose derivatives, starch, and starch derivatives; the antioxidant is selected from tocopherol, mixed tocopherols, ascorbyl palmitate, catechin, and ascorbic acid; the stabilizer is selected from glyceryl monostearate, sugar alcohols, or triglycerides; and the pH adjuster is citric acid. A stable curcuminoid composition selected from trisodium citrate, lactic acid, and magnesium carbonate; the solubilizing agent selected from lecithin, d-limonene, propylene glycol alginate, and sodium lauryl sulfate; the fat selected from medium-chain triglycerides, terpenes, and vegetable oils; and the anti-caking agent selected from colloidal silicon dioxide, magnesium stearate, stearic acid, and mannitol. Claim 2 A stable curcuminoid composition according to claim 1, wherein the curcuminoid is selected from one or more of curcumin, demethoxycurcumin, bisdemethoxycurcumin, or a mixture thereof. Claim 3 A stable curcuminoid composition according to claim 1, wherein the curcuminoid is present in a range of 10-90% w / w of the composition. Claim 4 A stable curcuminoid composition according to claim 1, wherein the composition has an increased bioavailability of 60 to 70 times compared to the reference. Claim 5 A stable curcuminoid composition according to claim 1, wherein the composition comprises a hydrophilic carrier in a range of 1-90% w / w of the composition. Claim 6 A stable curcuminoid composition according to claim 1, wherein the composition comprises an antioxidant in a range of 0.1-10% w / w of the composition. Claim 7 A stable curcuminoid composition according to claim 1, wherein the composition comprises a stabilizer in the range of 0.1-10% w / w of the composition. Claim 8 A stable curcuminoid composition according to claim 1, wherein the composition comprises a pH adjuster in the range of 0.1-10% w / w of the composition. Claim 9 A stable curcuminoid composition according to claim 1, wherein the composition comprises a solubilizing agent in the range of 0.1-40% w / w of the composition. Claim 10 A stable curcuminoid composition according to claim 1, wherein the composition comprises fat in the range of 0.1-40% w / w of the composition. Claim 11 A stable curcuminoid composition according to claim 1, wherein the composition comprises an anti-caking agent in the range of 0.1-10% w / w of the composition. Claim 12 A stable curcuminoid composition according to claim 1, wherein the composition is in the form of a tablet, capsule, mixed powder, licap, ointment, paste, lotion, liniment, mouthwash, gargle, consumable dry syrup, liquid syrup, health drink, diet drink, fruit juice, soft drink, etc. Claim 13 A stable curcuminoid composition according to claim 1, wherein the composition is in the form of granules and / or a powder or a mixture thereof. Claim 14 delete Claim 15 The composition of claim 1 is a stable curcuminoid composition that improves joint mobility and joint flexibility, reduces joint stiffness, improves walking ability, reduces cartilage degeneration, and reduces inflammation. Claim 16 The composition of claim 1 is a stable curcuminoid composition that reduces tumor necrosis factor-alpha (TNF-α), interleukin 1β (IL-1β), interleukin-6 (IL-6), collagen type 2, matrix metalloproteinase-3 (MMP3), cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), cartilage oligometric matrix protein (COMP); c-reactive protein (CRP), and malondialdehyde (MDA). Claim 17 The composition of claim 1 is a stable curcuminoid composition that increases interleukin-10 (IL-10), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT). Claim 18 delete Claim 19 A stable curcuminoid composition according to claim 1, wherein the subject is a human and / or animal. Claim 20 A stable curcuminoid composition according to claim 1, having a dosage of 10-1000 mg / kg.

Citation Information

Patent Citations

  • Water soluble formulation (liquid) of curcuminoids and process thereof

    WO2017175077A1